Cost-benefit analysis of lipid lowering therapy.
作者信息
Jönsson B, Johannesson M
出版信息
Eur Heart J. 1997 Jan;18(1):165-6. doi: 10.1093/oxfordjournals.eurheartj.a015099.
Abstract
摘要
相似文献
1
Cost-benefit analysis of lipid lowering therapy.降脂治疗的成本效益分析。
Eur Heart J. 1997 Jan;18(1):165-6. doi: 10.1093/oxfordjournals.eurheartj.a015099.
2
Cost-benefit analysis of lipid lowering therapy.降脂治疗的成本效益分析
Eur Heart J. 1996 Jul;17(7):974-5. doi: 10.1093/oxfordjournals.eurheartj.a015014.
3
Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.辛伐他汀。对其在血脂异常和冠心病治疗中成本效益的重新评估。
Pharmacoeconomics. 1997 Jan;11(1):89-110. doi: 10.2165/00019053-199711010-00010.
4
Therapy and clinical trials.治疗与临床试验。
Curr Opin Lipidol. 2002 Feb;13(1):109-11. doi: 10.1097/00041433-200202000-00017.
5
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.辛伐他汀和吉非贝齐治疗高脂血症的疗效及成本效益
Ann Acad Med Singap. 1992 Jan;21(1):34-7.
6
Reducing expenditures for statin-type lipid-lowering agents.降低他汀类降脂药物的支出。
Am J Health Syst Pharm. 1998 May 15;55(10):995-6, 999. doi: 10.1093/ajhp/55.10.995.
7
Implications of 4S evidence on baseline lipid levels.
Lancet. 1995 Jul 15;346(8968):181-2.
8
Descriptive study of lipid-modulating drug use in a French professional population.法国职业人群中脂质调节药物使用情况的描述性研究。
J Clin Epidemiol. 1994 Oct;47(10):1163-71. doi: 10.1016/0895-4356(94)90102-3.
9
Implications of 4S evidence on baseline lipid levels.
Lancet. 1995 Jul 15;346(8968):181.
10
Implications of 4S evidence on baseline lipid levels.4S研究证据对基线血脂水平的影响。
Lancet. 1995 Jul 15;346(8968):181.
Zotero 插件